Working for the future of personalized medicine

DNA Repair and cancer treatments



Detection of DNA Repair defects potentially increasing tumor mutational load.

Predict response to ImmunoTherapy



Identification of patients at risk of developing severe inflammation and adverse effects in response to radiotherapy.

Avoid Radiotoxicity

DNA Repair inhibitors


We check that drugs effectively impact DNA Repair activities.
We check for activation of compensatory mechanisms.

Predict response to DNA Repair Inhibitors

Tumor biopsy, blood cells

Targeted therapy


Refinement of the mutation-based classification of tumors identifies patient subtypes. Verification of the drug's functional impact.

Predict response to Targeted Therapy



Classification of tumors based on their true DNA Repair capacities.
Identification of activities up regulated and down regulated to optimize therapeutic strategies.

Predict Chemoresistance

Tumor biopsy, blood cells
Clinical Studies

LXRepair prospective clinical studies


Identifying early radiotoxicity biomarkers

Radiation induces oxidative stress and DNA strand-breaks. Side effects can be immune and inflammatory.
Base Excision Repair regulation in particular is closely linked to inflammation.
LXRepair's RAD-LX signature, by integrating patient's oxidative stress defences and their inflammation status, can potentially predict radiotoxicity events.
Our RIT clinical study, conducted under the supervision of Pr Nicolas Magne at Cancer Institute Lucien Neuwirt (Saint-Priest-en-Jarez) aims to investigate this predictive power.


Identifying chemo-radioresistance biomarkers in Head&Neck cancers

Several therapeutic options are available to patients with Head&Neck cancer. Surgery is indicated when the tumor is accessible.
For unresectable or non-operable tumors, induction chemotherapy (Cisplatin, 5-FU, Docetaxel) followed by radiotherapy or chemoradiotherapy is proposed. Other options include radiotherapy or chemoradiotherapy alone, or combinations. Treatment toxicity and intrinsic or acquired resistance limit the cure rate for patients .
We urgently need biomarkers to help select the best therapeutic option.

DNA Repair mechanisms are directly responsible for the tumor's response to these DNA-damaging therapies.

Given the complexity of the treatment and the complexity of DNA Repair mechanisms, single biomarkers are not informative enough.

LXRepair multiplex assays offer unmatched profiling solutions, providing a fuller understanding of the different cancer subtypes and allowing drivers of resistance and toxicity to treatments to be identified.

The SPOT-LX™ platform can identify relevant biomarkers from blood lymphocytes and tumor biopsies and predict treatment outcome.

The prospective ChemRadAssay clinical trial, conducted in collaboration with Hospice Civils de Lyon, Claude Bernard University, Grenoble Hospital and Centre Leon Bérard, aims to test this process.
ChemRad is supported by the CLARA Canceropole's "Preuve de Concept" program.


Improve stratification of melanoma

Resistance of melanoma to radiotherapy and chemotherapy is commonly attributed to specific regulation of DNA Repair.

Recent advances in our understanding of the molecular factors driving malignant transformation have led to the classification of melanoma based on specific gene mutations, and the development of targeted therapies. Notably, DNA Repair mechanisms are regulated by the MAPK/Pl3K/AKT signaling pathway.

The success of immunotherapy has further changed clinical management of melanoma. But patient responses to these treatments remain highly heterogeneous. There is thus a critical need to identify biomarkers to predict who will benefit from which therapy.

Exposure to UV radiation is a major risk factor for melanoma. Exposure to carcinogenic risk factors results in elevated mutation frequencies in tumors. Defective DNA Repair could be cause the elevated mutation frequencies observed in melanoma. Interestingly, the mutational load predicts a clinical benefit for immunotherapy in various cancers.

A unified strategy is required to class melanoma patients and direct selection of the most appropriate therapeutic option. Because of the central role played by DNA Repair in this carcinogen-induced tumor, we propose a new stratification based on functional DNA Repair analysis.

The first results obtained with melanoma patients confirmed that mutations in the MAPK pathways drive the DNA Repair Enzyme Signature, with some notable exceptions. Specific DNA Repair defects are detected in samples from some patients; these could lead to genomic instability and an elevated mutation load.
Patent pending

DX-kit pipeline

DX-kit pipeline overview

Biomarker development and validation
Product development
Proof of
Clinical assay



Assay predicting Radiotoxicity: CE-marking expected in 2020



Metastatic melanoma assay: Patent application filed on a new method of melanoma stratification to choose the best treatment



Head&Neck cancer assay: recruitments active (Preuve du Concept, cancéropole CLARA project)